IPR
Topic 104 Constitutional Public Health
Topic 104 — IP and Constitutional Law / Public Health
IP rights operate within constitutional constraints. The Indian Constitution does not explicitly mention IP — but Articles 14 (equality), 19(1)(a) (free speech), 19(1)(g) (right to occupation), 19(2) (reasonable restrictions), and Article 21 (right to life) collectively shape IP's constitutional foundations. The most consequential intersection is IP and PUBLIC HEALTH — patents on life-saving medicines collide with Article 21 right to health. This conflict found resolution in two foundational cases: NOVARTIS AG v. UNION OF INDIA (SC 2013) — Section 3(d) Patents Act anti-evergreening provision upheld; only NEW therapeutic efficacy patentable; "evergreening" of trivial modifications rejected. BAYER v. NATCO (Patent Office 2012) — India's first and only compulsory licence under Section 84 Patents Act; for Sorafenib (Nexavar), kidney/liver cancer drug; affordability and not-worked grounds satisfied. The TRIPS Doha Declaration 2001 affirmed national flexibilities for public health. Additional intersections: Article 19(1)(a) freedom of speech vs. copyright restrictions (Section 52 fair dealing balance); Article 19(1)(g) right to occupation vs. trademark protection; Article 14 challenges to IP statute provisions; Article 21 broader application. The Compulsory Licensing framework (Section 84 + Section 92 + Section 100) provides public interest tools. The 1978 Constitutional 44th Amendment removed property as a fundamental right but Article 21 protections remain vital. This topic walks through every aspect of IP-Constitutional intersection — fundamental rights framework, compulsory licensing, public health TRIPS flexibilities, and strategic considerations.
1. The Constitutional Framework for IP
A. Constitutional Articles Relevant to IP
Article | Provision | IP Relevance |
|---|---|---|
Article 14 | Equality before law. | Challenged Section 3(d) Patents Act. |
Article 19(1)(a) | Freedom of speech and expression. | Vs. copyright restrictions; Section 52 fair dealing. |
Article 19(1)(g) | Right to practice profession or occupation. | Vs. IP barriers to entry. |
Article 19(2) | Reasonable restrictions on Article 19(1). | Permits IP restrictions on speech. |
Article 19(6) | Reasonable restrictions on Article 19(1)(g). | Permits IP restrictions on occupation. |
Article 21 | Right to life and liberty. | Vs. patent monopolies on essential medicines. |
Article 31 (repealed 1978) | Right to property. | Was foundational; now Article 300A. |
Article 300A | Right to property (constitutional, not fundamental). | IP is property under broader interpretation. |
Article 47 | State duty to improve public health. | Directive Principle; supports compulsory licensing. |
Article 51 | State to foster respect for international law. | Supports TRIPS implementation balanced with national interests. |
B. The 1978 44th Amendment Impact
- Article 31 (Right to property as fundamental right) repealed.
- Article 300A introduced — property rights non-fundamental but constitutional.
- Significance: IP rights protected as legal, not fundamental rights.
- More flexibility for state regulation of IP.
- Supports public interest exceptions (compulsory licensing, fair dealing).
2. Article 21 — Right to Health vs. Patent Monopolies
A. The Constitutional Foundation
✅ Article 21 Right to Health Framework Constitutional foundation: · Article 21 — Protection of life and personal liberty. · Supreme Court interpretation extends to right to health. · Bandhua Mukti Morcha v. UoI (1984) — health within Article 21. · State of Punjab v. Mohinder Singh Chawla (1997) — right to medical care. · Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996) — emergency medical care. Applied to IP: · Patent monopolies on essential medicines vs. Article 21. · Constitutional duty to balance. · State has affirmative obligation under Article 47. · Section 84 compulsory licensing implements this balance. Landmark application: Bayer v. Natco (2012) — Sorafenib compulsory licence rooted in public health considerations within Article 21 framework. |
B. International Framework
- Universal Declaration of Human Rights — Article 25 right to health.
- International Covenant on Economic, Social and Cultural Rights (ICESCR) — Article 12 right to highest attainable standard of health.
- TRIPS Doha Declaration 2001 — public health flexibilities.
- Sustainable Development Goals (SDG 3) — health and wellbeing.
3. Compulsory Licensing — The Public Health Mechanism
A. The Statutory Framework
84 GROUNDS Section 84 | 92 GOVT USE Section 92 | 100 WITHOUT LIC Section 100 |
B. Section 84 Patents Act — Three Grounds
Section 84(1) Patents Act 1970 "At any time after the expiration of three years from the date of the grant of a patent, any person interested may make an application to the Controller for grant of compulsory licence on patent on any of the following grounds, namely:— (a) that the reasonable requirements of the public with respect to the patented invention have not been satisfied; or (b) that the patented invention is not available to the public at a reasonably affordable price; or (c) that the patented invention is not worked in the territory of India." |
C. Section 92 — Government Use for Public Emergency
- National emergency situations.
- Extreme urgency.
- Public non-commercial use.
- Government may grant compulsory licence on its own.
- Used during COVID-19 considerations.
D. Section 100 — Government Use Without Licence
- Government may use any patented invention.
- No royalty negotiation needed.
- Subject to reasonable compensation.
- Rarely invoked.
4. Bayer v. Natco — India's Only Compulsory Licence
📖 Natco Pharma Ltd. v. Bayer Corporation, 9 March 2012 (Patent Office, Mumbai); IPAB 4 March 2013 Facts — Bayer Corporation held Indian patent for Sorafenib (brand name Nexavar) — kidney and liver cancer drug. Bayer's Indian price: ~₹2.8 lakh per month treatment. Natco Pharma applied for compulsory licence to market generic at ~₹8,800 per month treatment. Section 84 Application: (a) Reasonable requirements of public not satisfied — only 2% of eligible patients reached. (b) Not available at reasonably affordable price — ₹2.8L/month inaccessible. (c) Not worked in India — Bayer imported finished product, did not manufacture in India. Patent Office (March 2012) — Compulsory licence granted to Natco; royalty 6% on net sales; field of use restrictions; quality control conditions. IPAB Appeal (March 2013) — Compulsory licence affirmed. Bombay HC + Supreme Court — Final affirmation. Significance — INDIA'S FIRST AND ONLY COMPULSORY LICENCE under Section 84: · Demonstrated TRIPS flexibilities operational. · Affordability ground primary. · Local working consideration. · Article 21 + Article 47 integration. · Foundational case for future compulsory licensing. · Subsequent applications (Lee Pharma 2015 for Saxagliptin) failed — Bayer v. Natco remains sole successful case. |
5. Novartis v. UoI — Section 3(d) Anti-Evergreening
📖 Novartis AG v. Union of India, AIR 2013 SC 1311; (2013) 6 SCC 1; Civil Appeal Nos. 2706-2716/2013 Facts — Novartis applied for patent on beta-crystalline form of Imatinib mesylate (Glivec) — leukemia treatment. India's Patents Act amended 2005 introduced Section 3(d) anti-evergreening provision. Patent Office rejected. IPAB rejected. Madras HC dismissed Article 14 challenge. Section 3(d) — Mere discovery of new form of known substance not patentable unless it differs significantly in efficacy. Issues — (i) Whether Section 3(d) violates Article 14? (ii) Whether Section 3(d) complies with TRIPS? (iii) Whether Glivec's beta-crystalline form satisfies "enhanced efficacy"? Holdings — Supreme Court (1 April 2013): (i) Section 3(d) constitutional; not arbitrary or vague. (ii) Section 3(d) within TRIPS flexibilities (Article 27). (iii) "Enhanced efficacy" must be THERAPEUTIC efficacy, not bioavailability. (iv) Glivec beta-crystalline form fails enhanced efficacy test. (v) Patent rejected. Significance — LANDMARK constitutional + TRIPS jurisprudence: · Section 3(d) anti-evergreening upheld. · Therapeutic efficacy as patentability test. · Public health considerations within TRIPS flexibilities. · Generic competition preserved for life-saving medicines. · Foundational for Indian pharmaceutical IP framework. |
6. Article 19(1)(a) Freedom of Speech vs. Copyright
A. The Tension
- Article 19(1)(a) — freedom of speech and expression.
- Copyright restricts reproduction of expressive works.
- Article 19(2) — reasonable restrictions permitted.
- Section 52 Copyright Act — fair dealing balance.
B. Section 52 Fair Dealing as Constitutional Implementation
- Private/research use.
- Criticism/review.
- News reporting.
- Educational use.
- Judicial proceedings.
- Parody/satire (limited recognition).
7. TRIPS Flexibilities and Public Health
A. Doha Declaration 2001
✅ TRIPS Doha Declaration 2001 — Foundation of Public Health Flexibilities Doha Declaration on TRIPS Agreement and Public Health (14 November 2001): Key principles: · "TRIPS Agreement does not and should not prevent Members from taking measures to protect public health." · Recognition of "gravity of public health problems afflicting many developing and least-developed countries." · Acceptance of TRIPS flexibilities for: - Compulsory licensing. - Parallel imports. - Public health emergencies. - Use of TRIPS provisions creatively. Indian application: · Section 3(d) — anti-evergreening. · Section 84 — compulsory licensing. · Section 92 — government use compulsory licensing. · Section 100 — government use without licence. · Section 47(3) — research/private use exception. · Patent challenges (pre-grant and post-grant opposition). India widely cited as model for TRIPS flexibility implementation. |
B. TRIPS Articles for Public Health
TRIPS Article | Provision |
|---|---|
Article 7 | Objectives — IP must contribute to social and economic welfare. |
Article 8 | Members may adopt necessary measures for public interest. |
Article 27.2 | Public order and morality exception (ordre public). |
Article 27.3 | Patentable subject matter exclusions (plants, animals, methods of treatment). |
Article 30 | Limited exceptions to patent rights. |
Article 31 | Compulsory licensing framework. |
Article 31bis (2017) | Permanent solution for compulsory licensing for export. |
Doha Declaration 2001 | Public health flexibilities affirmation. |
8. Recent Public Interest Cases
- Pfizer v. UoI — Sildenafil Citrate compulsory licence application.
- Lee Pharma v. AstraZeneca — Saxagliptin compulsory licence application (2015 rejected).
- BDR Pharmaceuticals v. Bristol-Myers Squibb — Dasatinib (2013 rejected).
- COVID-19 considerations (2020-2021) — compulsory licensing of COVID vaccines/treatments.
- Empagliflozin patent case (HP HC 30 May 2024) — credible challenge framework.
9. Strategic Considerations
✅ For pharmaceutical patentees — eight points For new drug applications, ensure Section 3(d) compliance (therapeutic efficacy enhancement). For local working, consider Indian manufacturing or licensed Indian generics. For pricing strategy, anticipate Section 84 affordability scrutiny after 3 years. For oppositions, anticipate pre-grant and post-grant challenges. For enforcement, balance commercial interests with public health considerations. For COVID-like emergencies, anticipate Section 92 government use. For litigation strategy, prepare for Article 21 considerations. For settlement, consider voluntary licensing as Section 84 alternative. |
✅ For challengers and public interest — six points For affordability claims, document Section 84 grounds comprehensively. For working requirements, evidence non-import status. For Section 3(d) challenges, focus on therapeutic efficacy lack. For pre-grant opposition, file with Patent Office. For Article 21 arguments, link to constitutional framework. For TRIPS arguments, leverage Doha Declaration flexibilities. |
🎯 EXAM POINTERS — TOPIC 104
|